Cube Labs SpA (MIL:CUBE) Gross-Profit-to-Asset % : -0.47% (As of Jun. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Cube Labs SpA Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Cube Labs SpA's annualized Gross Profit for the quarter that ended in Jun. 2023 was €-0.28 Mil. Cube Labs SpA's average Total Assets over the quarter that ended in Jun. 2023 was €59.07 Mil. Therefore, Cube Labs SpA's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2023 was -0.47%.

Cube Labs SpA Gross-Profit-to-Asset % Historical Data

The historical data trend for Cube Labs SpA's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cube Labs SpA Gross-Profit-to-Asset % Chart

Cube Labs SpA Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Gross-Profit-to-Asset %

3.48

20.40

2.71

0.88

0.84

Cube Labs SpA Semi-Annual Data
	Dec18	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial			1.01	0.75	0.11	1.56	-0.47

Competitive Comparison of Cube Labs SpA's Gross-Profit-to-Asset %

For the Asset Management subindustry, Cube Labs SpA's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cube Labs SpA's Gross-Profit-to-Asset % Distribution in the Asset Management Industry

For the Asset Management industry and Financial Services sector, Cube Labs SpA's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Cube Labs SpA's Gross-Profit-to-Asset % falls into.

Cube Labs SpA Gross-Profit-to-Asset % Calculation

Cube Labs SpA's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2022 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2022 )	/	( (Total Assets (A: Dec. 2021 )	+	Total Assets (A: Dec. 2022 ))	/ count )
	=	0.474	/	( (55.111	+	57.351)	/ 2 )
	=	0.474	/	56.231
	=	0.84 %

Cube Labs SpA's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Jun. 2023 )	/	( (Total Assets (Q: Dec. 2022 )	+	Total Assets (Q: Jun. 2023 ))	/ count )
	=	-0.278	/	( (57.351	+	60.788)	/ 2 )
	=	-0.278	/	59.0695
	=	-0.47 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Jun. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Cube Labs SpA Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Cube Labs SpA's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cube Labs SpA (MIL:CUBE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » Cube Labs SpA (MIL:CUBE) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Giulio Caccini, 1, Rome, ITA, 00186

Website

https://cube-labs.com

Cube Labs SpA operates as a venture builder that enables innovation in the healthcare technology space. The company is engaged in attracting sources of financing and providing entrepreneurial and operational support to the companies to develop healthcare technologies for the market.